全文获取类型
收费全文 | 3791篇 |
免费 | 284篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 91篇 |
妇产科学 | 75篇 |
基础医学 | 385篇 |
口腔科学 | 35篇 |
临床医学 | 532篇 |
内科学 | 664篇 |
皮肤病学 | 147篇 |
神经病学 | 362篇 |
特种医学 | 121篇 |
外科学 | 317篇 |
综合类 | 35篇 |
预防医学 | 580篇 |
眼科学 | 65篇 |
药学 | 359篇 |
中国医学 | 3篇 |
肿瘤学 | 296篇 |
出版年
2023年 | 12篇 |
2022年 | 34篇 |
2021年 | 92篇 |
2020年 | 51篇 |
2019年 | 80篇 |
2018年 | 87篇 |
2017年 | 65篇 |
2016年 | 71篇 |
2015年 | 88篇 |
2014年 | 113篇 |
2013年 | 172篇 |
2012年 | 238篇 |
2011年 | 297篇 |
2010年 | 143篇 |
2009年 | 144篇 |
2008年 | 258篇 |
2007年 | 251篇 |
2006年 | 232篇 |
2005年 | 227篇 |
2004年 | 224篇 |
2003年 | 204篇 |
2002年 | 195篇 |
2001年 | 38篇 |
2000年 | 32篇 |
1999年 | 43篇 |
1998年 | 31篇 |
1997年 | 42篇 |
1996年 | 26篇 |
1995年 | 30篇 |
1994年 | 21篇 |
1993年 | 16篇 |
1992年 | 30篇 |
1991年 | 31篇 |
1990年 | 24篇 |
1989年 | 24篇 |
1988年 | 27篇 |
1987年 | 20篇 |
1986年 | 18篇 |
1985年 | 17篇 |
1984年 | 19篇 |
1983年 | 11篇 |
1982年 | 16篇 |
1981年 | 15篇 |
1980年 | 12篇 |
1979年 | 9篇 |
1969年 | 11篇 |
1913年 | 28篇 |
1912年 | 19篇 |
1910年 | 13篇 |
1907年 | 9篇 |
排序方式: 共有4082条查询结果,搜索用时 15 毫秒
31.
OBJECTIVE: To describe the characteristics and systemic disease associations of episcleritis in childhood. DESIGN: Retrospective, observational case series. PARTICIPANTS: Twelve children diagnosed with episcleritis between July 1981 and June 1998. METHODS/TESTING: Complete eye and systemic evaluations. MAIN OUTCOME MEASURES: Characteristics of episcleritis and presence and nature of concurrent systemic disease. RESULTS: The 12 children (10 boys and 2 girls) ranged in age from 13 months to 16 years. Five children had bilateral simple episcleritis, one had bilateral nodular episcleritis, and six had unilateral simple episcleritis. The eye examination was otherwise normal and recovery was uneventful in all cases. Six of the nine children older than 5 years of age had one of the following rheumatologic diseases: systemic lupus erythematosus, juvenile rheumatoid arthritis, spondyloarthropathy, inflammatory bowel disease, rheumatic fever, or polyarteritis nodosa. All three children younger than 5 years of age had simple episcleritis, an antecedent viral illness, and presented within 2 months of each other. CONCLUSIONS: Episcleritis is a rare occurrence in childhood, especially in children younger than 5 years of age. In older children, it is frequently associated with rheumatologic disease. 相似文献
32.
33.
34.
Effects of a high-selenium yeast supplement on celecoxib plasma levels: a randomized phase II trial.
Denise H Frank Denise J Roe H-H Sherry Chow Jose M Guillen Karin Choquette Debra Gracie Jennifer Francis Airley Fish David S Alberts 《Cancer epidemiology, biomarkers & prevention》2004,13(2):299-303
A combination of celecoxib and selenium was used in a randomized double-blind Phase II trial as a preliminary study to a multicenter Phase III colorectal cancer chemoprevention trial using these two agents together. The purpose of this trial was to determine whether high-selenium baker's yeast [(Saccharomyces cerevisiae) 200 microg once daily] in combination with celecoxib (400 mg once daily) altered the steady-state plasma concentration of celecoxib or produced clinically significant toxicities. Seventy-three healthy subjects (ages 40-75 years) were recruited to the 6-week study from the general local population and were randomized to either the celecoxib plus selenized baker's yeast group or the celecoxib plus placebo group after a 2-week run in period of celecoxib only. Blood samples were taken at baseline (to document that there was no evidence of celecoxib intake), after the 2-week run-in period on celecoxib to verify steady-state blood levels of this agent, and at end of study (4 weeks postrandomization). Toxicities were monitored at 2 weeks after initiation of celecoxib, at 4 weeks after initiation, and at the end of the study. Blood level concentrations of celecoxib did not differ between the two groups as determined by high-performance liquid chromatography analysis nor were there significant differences in blood chemistry values between the two groups. Subjects' self-report of general physical toxicities was uncommon and limited to National Cancer Institute toxicity grade 2 or less; however, 2 female participants (3%) were removed from the study medications because of grade 2 edema and significant weight gain after 2 and 2.5 weeks of celecoxib administration. In conclusion, high-selenium yeast and celecoxib can be taken at the described doses with minimum short-term negative effects. In future Phase III chemoprevention trials of celecoxib, weight gain should be carefully monitored, and participants should be made aware of this potential side effect before study entry. 相似文献
35.
36.
Sherry A Ferguson F Javier Cisneros B Gough Joseph P Hanig Kimberly J Berry 《Toxicological sciences》2005,87(2):451-459
Oral treatment with the anti-acne drug Accutane (isotretinoin, 13-cis-retinoic acid) has been associated with suicide ideation and depression. Here, depression-like behaviors (i.e., behavioral despair and anhedonia) were quantified in adult Sprague-Dawley rats gavaged daily beginning at postnatal day (PND) 82 with 13-cis-RA (7.5 or 22.5 mg/kg) or all-trans-retinoic acid (10 or 15 mg/kg ). Tested at PND 130-131 in the Forced Swim Test, 7.5 mg/kg 13-cis-RA marginally decreased immobility and slightly increased climb/struggle durations whereas neither all-trans-retinoic acid group differed from controls. Voluntary saccharin solution (0.03%) intake at PND 102-104 and PND 151-153 was not different from controls in any treated group, although all RA-treated groups had lower intakes. Swim speed in a water maze at PND 180 was similar across groups, indicating no RA-induced differences in physical ability. Open field activity was mildly decreased at PND 91 in 7.5 mg/kg-treated males only, but it was within the control range at PND 119, 147, and 175. Thus, at serum levels similar to those in humans receiving the drug, chronic 13-cis-RA treatment did not severely affect depression-like behaviors in rats. These data do not substantiate the hypothesis of 13-cis-RA-induced depression. 相似文献
37.
38.
Mace L Rothenberg Bonnie LaFleur Donna E Levy Mary Kay Washington Sherry L Morgan-Meadows Ramesh K Ramanathan Jordan D Berlin Al B Benson Robert J Coffey 《Journal of clinical oncology》2005,23(36):9265-9274
PURPOSE: The clinical objective of this trial was to evaluate gefitinib in patients with metastatic colorectal cancer that had progressed despite prior treatment. Serial tumor biopsies were performed when possible and analyzed for activation of the epidermal growth factor receptor (EGFR) signaling pathway. Serial serum samples were measured for amphiregulin and transforming growth factor-alpha (TGFalpha). PATIENTS AND METHODS: One hundred fifteen patients were randomly assigned to receive gefitinib 250 or 500 mg orally once a day. One hundred ten patients were assessable for clinical efficacy. Biologic evaluation was performed on paired tumor samples from 28 patients and correlated with clinical outcome. RESULTS: Median progression-free survival was 1.9 months (95% CI, 1.8 to 2.1 months) and 4-month progression-free survival rate was 13% +/- 5%. One patient achieved a radiographic partial response (RR = 1%; 95% CI, 0.01% to 5%). Median survival was 6.3 months (95% CI, 5.1 to 8.2 months). The most common adverse events were skin rash, diarrhea, and fatigue. In the biopsy cohort, expression of total or activated EGFR, activated Akt, activated MAP-kinase, or Ki67 did not decrease following 1 week of gefitinib. However, a trend toward decreased post-treatment levels of activated Akt and Ki67 was observed in patients with a PFS higher than the median, although these did not reach the .05 level of significance. CONCLUSION: Gefitinib is inactive as a single agent in patients with previously treated colorectal cancer. In tumor samples, gefitinib did not inhibit activation of its proximal target, EGFR. Trends were observed for inhibition of downstream regulators of cellular survival and proliferation in patients achieving longer progression-free survival. 相似文献
39.
Ronald C Wester Xiaoying Hui Sherry Barbadillo Howard I Maibach Yvette W Lowney Rosalind A Schoof Stewart E Holm Michael V Ruby 《Toxicological sciences》2004,79(2):287-295
This study was conducted to evaluate the dermal absorption of arsenic from residues present on the surface of wood preserved with chromated copper arsenate (CCA). The research reported herein used methods parallel to those of earlier research on the dermal absorption of radiolabeled arsenic (R. C. Wester et al., 1993, Fund. Appl. Toxicol. 20, 336-340), with modifications to allow use of environmental matrices that are not radiolabeled. These modifications include the surface area of application and dietary intake of arsenic, thus maximizing the potential for detection of dermally absorbed arsenic in exposed animals above diet-associated background levels of exposure. Two forms of arsenic were administered in this work. The first, arsenic in solution, was applied to the skin of monkeys to calibrate the model against prior absorption research and to serve as the basis of comparison for absorption of arsenic from CCA-treated wood residues. The second substrate was residue that resides on the surface of CCA-treated wood. Results from this research indicate that this study methodology can be used to evaluate dermally absorbed arsenic without the use of a radiolabel. Urinary excretion of arsenic above background levels can be measured following application of soluble arsenic, and absorption rates (0.6-4.4% absorption) are consistent with prior research using the more sensitive, radiolabeled technique. Additionally, the results show that arsenic is poorly absorbed from CCA-treated wood residues (i.e., does not result in urinary arsenic excretion above background levels). 相似文献
40.